Ananda Ghosh, an analyst from H.C. Wainwright, maintained the Buy rating on Structure Therapeutics, Inc. Sponsored ADR. The associated price target remains the same with $60.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ananda Ghosh’s rating is based on the promising potential of Structure Therapeutics’ aleniglipron, an oral GLP-1 therapy, which is positioned to address a significant gap in the current incretin-based therapies landscape. The analysis highlights that while injectable therapies like tirzepatide have set high efficacy standards, oral alternatives such as orforglipron have shown substantial weight loss but suffer from gastrointestinal side effects.
Aleniglipron’s ongoing Phase 2b ACCESS studies are designed to optimize efficacy while minimizing side effects through a ‘low and slow’ titration strategy. This approach aims to achieve a weight loss efficacy in the 10-12% range with improved tolerability, potentially offering a differentiated oral profile. If successful, this could justify advancing to Phase 3 trials and enhance the company’s acquisition prospects, with a potential stock upside of 25-30%.
In another report released yesterday, Jefferies also maintained a Buy rating on the stock with a $79.00 price target.